37 results about "Biphosphonate" patented technology

The invention discloses a production method of flame-retardant polyester fabric. The production method comprises the following steps: adding carbon tetrachloride, phosphorus trichloride and pentaerythritol in a four-hole boiling flask in sequence and stirring, dripping bromine water in the four-hole boiling flask at a low temperature, meanwhile, exhausting the generated hydrogen chloride gas, reacting for a certain time, and postprocessing to obtain a chloro-biphosphonate flame retardant; jetting the solid chloro-biphosphonate flame retardant on the polyester fabric for 20 to 30 minutes through a vacuum magnetron sputtering instrument, and drying the polyester fabric at a low temperature to obtain the flame-retardant polyester fabric. Through the manner, the production method of the flame-retardant polyester fabric, which is provided by the invention, is simple to operate, has a low requirement on the operation proficiency of personnel and saves the labor cost; and the flame-retardant polyester fabric takes a self-extinguishing effect, is green and environment-friendly, and less in environmental pollution, does not generate melted drippings at a high temperature but is charred, and does not cause secondary damage.

A method for delivering a bisphosphonate and / or strontium ranelate below the surface of a bone using a mechanical force. The method includes the steps of combining a bisphosphonate and / or strontium ranelate with a carrier to form a delivery composition and delivering an effective amount of the delivery composition below the surface of the bone with a mechanical force. Also provided is a method for strengthening a portion of a bone. This method includes the step of delivering an effective amount of a bisphosphonate and / or strontium ranelate below the surface of a portion of a bone with a mechanical force.

The present inven tion is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also disclosed.

The invention discloses a method for preparing a monophosphonate and biphosphonate mixed fire retardant, which comprises the following steps of: (1) heating tris phosphite and dihalide in the presence of a catalyst: (2) refluxing the mixture after the temperature rises to 110 to130 DEG C and continuously heating the refluxed mixture, wherein the optimal refluxing temperature of 120 DEG C; (3) allowing the refluxing speed to reduce obviously when the temperature is 160 and 180 DEG C, wherein the optimal temperature is 170 DEG C; (4) continuing a reaction, keeping the temperature between 170 and 200 DEG C to perform a reaction for 1 hour when the reflux phenomenon basically disappears, wherein the reaction is performed at 180 to190 DEG C optimally; (5) distilling the reacting product under normal pressure and filtering the distilled product to obtain a colorless transparent product. The total product yield of the monophosphonate and biphosphonate mixed fire retardant is over 90 percent; and the reaction time is shortened, the product has good color and luster, the acid value is low, the viscosity is low and no additional de-coloration treatment is required. Serving as the additive-type phosphine fire retardant, the monophosphonate and biphosphonate mixed fire retardant has higher performance. The monophosphonate and biphosphonate mixed fire retardant has the advantages of high economy, high product utilization efficiency, zero emission in a production process and environmental protection.

The novel bisphosphonic acid ester derivatives represented by the following formula (1):Y—Cy—(NH)m—(CH2)n—C(X)(PO(OR1)(OR2))2  (1)wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.

Synthesis of biphosphonate compounds can be advantageously carried out in a solvent / diluent comprising a compound of formula (3)wherein R is hydrogen or a C1-C6 alkyl group; each of R1 is a C1-C6 alkyl group or both R1 groups are linked to form a C1-C3 alkylene group; and R2 is hydrogen, a C1-C6 alkyl group, a C1-C6 alkoxy group, or is linked together with R to form a C3-C7 carbon ring.

The invention provides the use of a derivative with C-O-P bonds in the form of controlled release for the treatment of patients with renal failure. The invention also relates to the use of the derivative together with other active substances, that can particularly be selected from the list comprising a calcimimetic, a vitamin, a phosphorus chelator, thiosulfate, biphosphonate, pyrophosphate, citrate, a diuretic, an antihypertensive and an anticholesterolemic agent.

The present invention relates to a kind of biphosphonates, which have double medicinal functions and are compounds formed with biphosphonic acid and medicinal organic base. The present invention also relates to their preparation and application.

The present invention describe nanocomplexes also called auto-assembling nanoparticles comprising biphosphonates, lipid nanovectors and inorganic nanovectors.In particular the invention describes zoledronic acid complexed with calcium phosphate base nanoparticles; said particles in their turn mixed with lipidic particles e.g. liposomes.Said nanocomplexes are useful, and showed to be efficient in vivo, as pharmaceutical formulations of biphosphonates for the treatment or prevention of tumor growth and / or metastasis. Tumors can be solids and / or haematological such as prostate, lung, head / neck, colon, liver, breast, pancreas, kidneys, bladder, male and female urogenital tract, bones, multiple myeloma, primitive and secondary tumors of the central nervous system and lymphomas.

The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.